• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Rituximab
    2 Drugs classified under this active ingredient


    All the Active Ingredient Drugs

    MabThera
    Roche
    RX
    partial basket chart
    MabThera

    Monoclonal Antibody. Rituximab 10 mg/ml.
    VIALS (conc. for sol. for infus.): 2 x 100
    mg/10 ml; 1 x 500 mg/50 ml. NHL: 375
    mg/m2 as cont. infus: In prev. untreat.
    pts: In comb. with chemother. given on
    day 1 of ea. cycle for 8 cycles. In
    relapsed/refract. pts: As single agent 1
    wkly for 4 doses. Prev. untreat. pts:
    Mainten. ther: 375 mg/m2 bdy surface
    1 x every 2 mths until dis. progr./max.
    2 yrs. Pts. respond. to induct. tmt. may
    receive maint. ther. at 375 mg/m2 bdy
    surface 1 x every 3 mths until dis.
    progress or for max. period 2 years.
    Chron. lymphocytic leuk. (CLL): 375
    mg/m2 on day 1 of 1st tmt cycle, foll.
    by 500 mg/m2 on day 1 of ea.
    subsequent cycle for 6 cycles total.
    ANCA-associated Vasculitis (AAV): 375
    mg/m2 body surface, as I.V. infus 1 x
    wkly for 4 wks. Methylprednisolone
    1,000 mg I.V. dly for 1-3 days is
    recommend. to treat severe vasculitis
    sympts, follow. by oral prednisone 1
    mg/kg/day (max. 80 mg/day), and
    tapered as rapidly as poss. per clin.
    need) during and aft. tmt.
    Tmt. previous untreated pts. with III-IV
    follicular lymphoma in comb. with
    chemother. Tmt. relapsed or refract. lowgrade
    or follicular B-cell non-Hodgkin’s
    lymphoma, CD20 positive diffuse large
    B-cell non-Hodgkin’s lymphoma in comb. with CHOP chemother. Maint. ther. for
    tmt. follic. lymphoma pts. respond. to
    induct. ther. First line tmt. chron.
    lymphocytic leuk. (CLL) in comb. with
    chemother. Rheum. arthrit: In comb. with
    methotrexate, to reduce signs and sympts.
    in adult pts. with mod-severe active RA
    who had inad. response/intol. to one or
    more TNF antagonist ther. ANCAassociated
    vasculitis (AAV): In combinat.
    with glucocorticoids, tmt. of adults with
    Wegener’s Granulomatosis (WG) and
    Microscopic Polyangiitis (MPA).

    Truxima
    Perrigo
    RX
    partial basket chart
    Truxima

    Monoclonal Antibody. Rituximab 100 mg, 500 mg.
    VIAL (concentr. for sol. for infus.): 1×50ml, 2×10ml. Dosage must be adjust. individ. for each pt.
    Indicated in adult. for: Non-Hodgkin’s lymphoma. (NHL) for the tmt. of pts. with relaps. or refract. low-grade or folic., B-cell non-hodgkin’s lymphoma. Tmt. of previous. untreat. pts. with low-grade or folic. lymphoma in comb. with chemother. Tmt. of pts. with CD20 posit. diffuse large B-cell non-Hodgkin's lymphom. in comb. with CHOP chemother. Maintenan. ther. is indic. for the tmt. of folic. lymphom. pts. respond. to induct. ther.
    CLL: in comb. with chemother. is indic. for the tmt. of pts. with previous. untreated and relaps./refract. CLL. Only limited data are available on efficacy and safety for pts. previous. treated with MABS includ. rituximab or pts. refract. to prev. rituximab plus chemother.
    Granulomatosis with polyangiitis & microscopic polyangiitis: In comb. with glucocorticoids, is indic. for the tmt. of adult pts. with granulomatosis with polyangiitis (GPA) (Wegener’s Granulomatosis (WG)) and microscopic polyangiitis (MPA).
    C/I: For the use in non-Hodgkin’s lymphom., CLL&granulomatosis with polyangiitis & microscopic polyangiitis. Hypersens. Active, severe infec. Pts. in a severely immunocomprom. state. Specific for granulomatosis with polyangiitis & microscopic polyangiitis: Severe HF (NYHA Class IV) or severe, uncontrol. card. dis. See lit.

    CLOSE